CRVS
CorvusยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CRVS Profile
Corvus Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing immuno-oncology therapies to enhance the immune systems of patients with solid tumors and cancer
901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080
--
Corvus Pharmaceuticals, Inc., was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immunotherapeutic oncology programs designed to use the immune system to attack cancer cells. Since the start of operations in November 2014, four immuno-oncology programs have been built, three of which focus on the adenosine cancer axis regulating the immune response pipeline. The company's lead product candidate, CPI-444, A2A receptor adenosine, is an oral small molecule antagonist for immune checkpoints.
